Open Access. Powered by Scholars. Published by Universities.®
Antipsychotics;; adherence;; depot;; long-acting injection;; meta-analysis;; relapse;; schizophrenia;; treatment discontinuation;; SCHIZOAFFECTIVE DISORDER;; FLUPHENAZINE DECANOATE;; MAINTENANCE TREATMENT;; CLINICAL-TRIAL;; TERM TREATMENT;; DOUBLE-BLIND;; OPEN-LABEL;; RISPERIDONE;; THERAPY;; OLANZAPINE;; Psychiatry
Articles 1 - 1 of 1
Full-Text Articles in Medical Molecular Biology
Long-Acting Injectable Vs Oral Antipsychotics For Relapse Prevention In Schizophrenia: A Meta-Analysis Of Randomized Trials, Taishiro Kishimoto, A. Robenzadeh, C. Leucht, S. Leucht, K. Watanabe, M. Mimura, M. Borenstein, John Kane, Christoph Correll
Long-Acting Injectable Vs Oral Antipsychotics For Relapse Prevention In Schizophrenia: A Meta-Analysis Of Randomized Trials, Taishiro Kishimoto, A. Robenzadeh, C. Leucht, S. Leucht, K. Watanabe, M. Mimura, M. Borenstein, John Kane, Christoph Correll
Journal Articles
Background: While long-acting injectable antipsychotics (LAIs) are hoped to reduce high relapse rates in schizophrenia, recent randomized controlled trials (RCTs) challenged the benefits of LAIs over oral antipsychotics (OAPs). Methods: Systematic review/meta-analysis of RCTs that lasted = 6 months comparing LAIs and OAPs. Primary outcome was study-defined relapse at the longest time point; secondary outcomes included relapse at 3, 6, 12, 18, and 24 months, all-cause discontinuation, discontinuation due to adverse events, drug inefficacy (ie, relapse + discontinuation due to inefficacy), hospitalization, and nonadherence. Results: Across 21 RCTs (n = 5176), LAIs were similar to OAPs for relapse prevention at …